Safety Alert: Mycophenolate
Cases of Anemia Reported in Patients Treated with CellCept
Roche notified healthcare professionals that cases of Pure Red Cell Aplasia (PRCA) have been reported in patients treated with CellCept (mycophenolate mofetil) in combination with other immunosuppressive agents. Pure Red Cell Aplasia is a type of anemia where the bone marrow slows or stops production of red blood cells. The WARNINGS and ADVERSE REACTIONS sections of the CellCept Prescribing Information have been revised to reflect this new safety information.
For more information, please visit:
What does this mean?
CellCept is used to prevent organ transplant rejection. For most patients, the benefits of Cellcept will outweigh the possible risk of Pure Red Cell Aplasia. Symptoms of Pure Red Cell Aplasia include fatigue, lethargy, tiredness, and/or abnormal paleness of the skin. If you are taking Cellcept, you can watch for these symptoms and contact your doctor immediately if they occur.
If you have any questions or concerns about Cellcept or this alert, please follow up with your doctor.
